KUALA LUMPUR (Bernama) — Duopharma Biotech Bhd
’s net profit for the second quarter ended June 30, 2021 increased to RM15.39 million from RM14.73 million recorded in the same period last year.
Revenue rose to RM155.44 million from RM143.33 million previously, the group said in a filing with Bursa Malaysia today.
It said the good result was supported by higher sales to the consumer healthcare and public health sector.
“The company has also declared an interim dividend of 0.5 sen per share for the current quarter, equivalent to RM3.53 million. The board of directors has resolved that the dividend reinvestment plan shall not apply to this dividend,” it said.
Its group managing director Leonard Ariff Abdul Shatar said stringent operational cost control measures will continue to help the company navigate the challenging external environment during the pandemic.
“The pandemic has caused huge uncertainties in the business environment and resulted in disruptions in the global supply chain. In our industry, players are faced with issues such as purchasing certain raw and packaging materials. We seek to overcome these challenges by managing the risks the best we can,” he said.
